Myasthenia Gravis Clinical Trials

54 recruiting

Myasthenia Gravis Trials at a Glance

90 actively recruiting trials for myasthenia gravis are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 3 with 20 trials, with the heaviest enrollment activity in Warsaw, Naples, and Houston. Lead sponsors running myasthenia gravis studies include argenx, Huashan Hospital, and Alexion Pharmaceuticals, Inc..

Browse myasthenia gravis trials by phase

Treatments under study

About Myasthenia Gravis Clinical Trials

Looking for clinical trials for Myasthenia Gravis? There are currently 54 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myasthenia Gravis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myasthenia Gravis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 90 trials

Recruiting
Phase 2Phase 3

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Generalized Myasthenia Gravis
Shanghai Jiaolian Drug Research and Development Co., Ltd104 enrolled18 locationsNCT06447597
Recruiting
Phase 3

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled99 locationsNCT06744920
Recruiting
Phase 2Phase 3

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 2Phase 3

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL12 enrolled13 locationsNCT06149559
Recruiting
Phase 2Phase 3

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
argenx12 enrolled20 locationsNCT06392386
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled10 locationsNCT07294170
Recruiting
Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled9 locationsNCT07284420
Recruiting
Phase 3

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled81 locationsNCT07039916
Recruiting
Phase 3

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled133 locationsNCT06463587
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled3 locationsNCT07304154
Recruiting

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
AstraZeneca50 enrolled14 locationsNCT06909253
Recruiting
Phase 2

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
Vertex Pharmaceuticals Incorporated30 enrolled3 locationsNCT07501702
Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled5 locationsNCT07247279
Recruiting
Phase 2

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Myasthenia GravisMyasthenia Gravis, MuSK
NMD Pharma A/S84 enrolled40 locationsNCT06414954
Recruiting
Phase 3

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Myasthenia Gravis
Janssen Research & Development, LLC115 enrolled8 locationsNCT07217587
Recruiting
Not Applicable

TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls

Myasthenia Gravis
Yi Ting Yeh100 enrolled1 locationNCT06754020
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 4

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.75 enrolled12 locationsNCT07221838
Recruiting
Phase 3

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

Myasthenia Gravis, Ocular
RemeGen Co., Ltd.120 enrolled1 locationNCT07249632
Recruiting
Phase 1Phase 2

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled10 locationsNCT06704269